USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $14.57 and traded as high as $14.90. USANA Health Sciences shares last traded at $14.7150, with a volume of 175,944 shares trading hands.
Wall Street Analyst Weigh In
A number of analysts have commented on USNA shares. Zacks Research upgraded shares of USANA Health Sciences from a "strong sell" rating to a "hold" rating in a research note on Monday, October 5th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of USANA Health Sciences in a research note on Monday, September 21st. Finally, Wall Street Zen lowered shares of USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Reduce".
Get Our Latest Stock Analysis on USNA
USANA Health Sciences Stock Up 2.8%
The company has a market cap of $271.93 million, a PE ratio of -12.16, a PEG ratio of 1.60 and a beta of 0.68. The company has a 50-day moving average of $14.57 and a 200-day moving average of $18.10.
USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.50). The company had revenue of $223.27 million for the quarter, compared to the consensus estimate of $235.00 million. USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%. As a group, equities analysts predict that USANA Health Sciences, Inc. will post 0.76 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in USANA Health Sciences during the second quarter valued at about $33,182,000. Pzena Investment Management LLC purchased a new stake in USANA Health Sciences during the second quarter worth about $25,739,000. Empowered Funds LLC bought a new stake in USANA Health Sciences in the second quarter worth about $1,500,000. Nantahala Capital Management LLC bought a new stake in USANA Health Sciences in the second quarter worth about $17,295,080. Finally, Bank of New York Mellon Corp bought a new stake in USANA Health Sciences in the second quarter worth about $1,105,000. Hedge funds and other institutional investors own 54.25% of the company's stock.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.
Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.
The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.